The study conducted by Jianming Wang et al. revealed that administration of recombinant leukemia inhibitory factor (rLIF) protected mice from GVHD-induced tissue damage and mortality without compromising graft-versus-leukemia activity. This evidence concerns the gene LIF and graft versus host disease.